Quick Summary
Nirmacom Tabalet
Last updated on 26 Sep 2026 | 08:41 AM (IST)
₹792
MRP: ₹980
(You Save ₹188)
3 TABLET(s) IN A STRIP
19% OFF
₹792
MRP: ₹980.00
Inclusive of all taxes
19% Off
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Better Service Satisfied Customers
Introduction
Nirmacom Tablet contains the antiviral combination of Nirmatrelvir and Ritonavir, used to treat mild to moderate COVID-19 in adults at high risk of developing severe disease. This treatment is aligned with the expected Nirmacom mechanism of action, where Nirmatrelvir acts as a SARS-CoV-2 protease inhibitor that blocks viral replication, and Ritonavir boosts its effectiveness by slowing its breakdown in the body.
This medicine works best when taken early in the course of infection, ideally within five days of symptom onset. Nirmacom dosage is determined by the prescribing physician based on clinical condition, risk factors, and potential drug interactions. It is commonly prescribed for individuals with risk factors such as diabetes, hypertension, chronic lung disease, heart disease, weakened immunity, cancer, or advanced age.
Nirmacom Tablet is not a substitute for vaccination and does not prevent COVID-19 infection. It is not recommended in patients with severe liver or kidney disease, and it should not be used by individuals allergic to any component of the formulation. For patients evaluating treatment costs, the Nirmacom price may vary depending on pharmacy and region.
When sourcing the medication, ensure that Nirmacom Tablet is purchased from trusted pharmacies or verified online medical platforms to guarantee authenticity and safe usage.
Uses
Nirmacom Tablet uses are:
Treatment of mild to moderate COVID-19 in adults at high risk of progression to severe disease, hospitalisation, or death.
How Nirmacom Tablet Works
Nirmacom contains two active components:
1. Nirmatrelvir
Inhibits the SARS-CoV-2 main protease enzyme (Mpro).
The virus requires Mpro to process polyproteins, which are essential for replication.
Blocking Mpro prevents viral multiplication inside human cells.
2. Ritonavir
Ritonavir is not active against COVID-19 on its own.
It boosts Nirmatrelvir by inhibiting CYP3A4, the enzyme that metabolises it.
This increases Nirmatrelvir levels and maintains its therapeutic activity.
Together, the combination reduces viral load in the body and helps prevent worsening of symptoms.
Interaction of Nirmacom Tablet with Other Drugs
Nirmacom has significant drug interactions, mainly due to Ritonavir’s strong effect on liver enzymes.
Inform your doctor if you take:
Cholesterol medications (lovastatin, simvastatin)
Heart rhythm drugs (amiodarone, flecainide)
Antibiotics (rifampicin)
Anticonvulsants (carbamazepine, phenytoin)
Blood thinners (warfarin, apixaban, rivaroxaban)
Immunosuppressants (tacrolimus, cyclosporine)
Anti-anxiety or sleep medicines (triazolam, midazolam)
Herbal supplements (St. John's Wort)
Some of these combinations may cause dangerous side effects. Never self-medicate; always consult a healthcare provider.
Storage conditions
Store below 30°C in a dry place.
Keep tablets in their original blister pack.
Protect from moisture and direct sunlight.
Keep out of reach of children.
How to take Nirmacom Tablet
Take the tablets orally, with or without food.
Swallow tablets whole; do not crush or chew.
Treatment typically lasts 5 days, as prescribed by your doctor.
Start medication as soon as possible after confirming a COVID-19 infection.
If you miss a dose and it has been less than 8 hours since your last dose, take it immediately. Otherwise, skip it and continue the regular schedule. Do not double the dose.
Safety Advices
Pregnancy
Consult your doctor. Limited safety data is available in pregnancy. Use only if the potential benefit outweighs the risk.
Breast Feeding
Consult your doctor. Ritonavir may pass into breast milk. Breastfeeding may need to be paused during treatment.
Lungs
Use with caution. Not recommended in patients with severe lung impairment.
Liver
Use with caution. Not recommended in patients with severe liver impairment.
Alcohol
Consult your doctor. Alcohol may worsen illness-related fatigue and interact with medications.
Driving
Nirmacom may cause dizziness or fatigue in some individuals. Avoid driving until you know how the medicine affects you.
Side Effects
Nirmacom side effects are
Serious Side Effects:
Severe allergic reaction (swelling, breathing difficulty)
Hepatitis or liver enzyme elevation
Significant drug interaction effects
Irregular heartbeat
Severe abdominal pain
Common Side Effects:
Altered taste (metallic taste)
Diarrhea
High blood pressure
Muscle aches
Nausea or vomiting
Headache
Contact your doctor if symptoms worsen or do not improve.
Expert tips
Start Nirmacom within 5 days of symptoms for best results.
Do not stop or skip doses, even if symptoms improve early.
Inform your doctor about ALL current medications.
Stay hydrated, rest well, and monitor oxygen levels if advised.
This medicine is not for preventive use and is not a replacement for vaccination.
Continue isolation and safety measures as recommended.
FAQs
Q1.
What is Nirmacom Tablet used for?
It is used to treat mild to moderate COVID-19 in adults who are at high risk of severe disease.
Q2.
How soon should I start taking Nirmacom?
Ideally, within 5 days of the onset of symptoms.
Q3.
Can I take Nirmacom with my regular medicines?
Some medicines interact strongly with Nirmacom. Always check with your doctor before combining medications.
Q4.
Does Nirmacom prevent COVID infection?
No. It is not a preventive medication or vaccine substitute.
Q5.
Is Nirmacom effective against new variants?
Nirmatrelvir targets a viral enzyme that mutates less frequently, and evidence suggests activity against multiple variants.
Fact Box
Molecule Name | Nirmatrelvir + Ritonavir |
Therapeutic Class | Antiviral |
Pharmacological Class | Protease Inhibitor Combination |
Indications | Treatment of mild to moderate COVID-19 in high-risk adults. |
References
Hammond J. et al. (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa2118542?
Pfizer. Paxlovid (Nirmatrelvir + Ritonavir) Emergency Use Authorization Fact Sheet https://www.fda.gov/media/155050/download?
World Health Organization (WHO) COVID-19 Treatment Guidelines https://www.who.int/therapeutics?
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Vikas B S
Pharm D
Reviewed By
Dr. Abhishaanth Prabu
MBBS
Last updated : 26 Sep 2026 | 08:41 AM (IST)
Want to know more?
Read Our Editorial Policy